Status:
COMPLETED
Treatment of Slow-flow After Primary Percutaneous Coronary Intervention With Flow-mediated Hyperemia
Lead Sponsor:
Fundación EPIC
Collaborating Sponsors:
Barcicore-Lab
Conditions:
Coronary Microvascular Disease
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A total of 100 patients with ST-elevation myocardial infarction (STEMI) presenting slow-flow after primary-percutaneous coronary intervention (PPCI) will be randomized to pharmacologic treatment with ...
Detailed Description
Slow-flow phenomena is observed around 15% of patients undergoing PPCI and has been associated with poor prognosis. Hyperemic drugs, such as nitroprussiate and adenosine, have not yet demonstrated to ...
Eligibility Criteria
Inclusion
- ST elevation myocardial infarction Killip I \<12 hours since symptoms onset.
- ST elevation \> 2 mm anterior leads or \> 1 mm inferior or lateral leads.
- Sustained slow coronary flow (TIMI flow 0-2) for at least 30 seconds after stent implantation or stent post-dilatation.
Exclusion
- Previous myocardial infarction in the culprit artery
- Previous stroke
- Advanced kidney disease (creatinine clearance \<30 ml / min).
- Active bleeding
- Allergy to contrast, nitroprussiate or adenosine.
- Culprit lesion in coronary bypass, left main coronary artery or stent thrombosis
- Macroscopic thrombus embolization in the infarct-related artery
Key Trial Info
Start Date :
January 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04685941
Start Date
January 25 2021
End Date
October 31 2022
Last Update
November 10 2022
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
2
Hospital del Mar
Barcelona, Spain, 08003
3
Hospital Clínic de Barcelona
Barcelona, Spain, 08036
4
Hospital Universitario Puerta del Mar
Cadiz, Spain, 11009